Australia - English - Department of Health (Therapeutic Goods Administration)

claris lifesciences australia pty ltd - ondansetron hydrochloride dihydrate -

United States - English - NLM (National Library of Medicine)

claris life sciences inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin 1 g - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli,2 klebsiella spp.2 (including k. pneumoniae2 ), proteus mirabilis,2 bacteroides fragilis,2 enterobacter spp.,2 and acinetobacter calcoaceticus.2 note: for information on use in pediatric patients see precautions – pediatric use and clinical studies sections.  intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae2 ), bacteroides spp. (including b. fragilis ), and enterobacter spp.2 gynecological infections caused by beta-lactamase producing strains of escherichia coli,2  and bacteroides spp.2 (including b. fragilis2 ). __________ 2 efficacy for this microorganism in this organ system was studied in fewer than 10 infec

Australia - English - Department of Health (Therapeutic Goods Administration)

claris lifesciences australia pty ltd - fluconazole -

United States - English - NLM (National Library of Medicine)

claris lifesciences, inc. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin 250 mg - ampicillin for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: respiratory tract infections caused by s. pneumoniae (formerly d. pneumoniae ). staphylococcus aureus (penicillinase and nonpenicillinase-producing), h. influenzae, and group a beta-hemolytic streptococci. bacterial meningitis caused by e. coli, group b streptococci, and other gram-negative bacteria (listeria monocytogenes, n. meningitidis ). the addition of an aminoglycoside with ampicillin may increase its effectiveness against gram-negative bacteria. septicemia and endocarditis caused by susceptible gram-positive organisms including streptococcus sp., penicillin g-susceptible staphylococci, and enterococci. gram-negative sepsis caused by e. coli, proteus mirabilis and salmonella sp. respond to ampicillin. endocarditis due to enterococcal strains usually respond to intravenous therapy. the addition of an aminoglycoside may enhance the effe

Australia - English - Department of Health (Therapeutic Goods Administration)

claris lifesciences australia pty ltd - metronidazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

claris lifesciences australia pty ltd - frusemide -

United States - English - NLM (National Library of Medicine)

claris lifesciences, inc. - nafcillin sodium (unii: 49g3001bck) (nafcillin - unii:4cnz27m7rv) - nafcillin 1 g - nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see clinical pharmacology - susceptibility tests ). nafcillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. nafcillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus , therapy should not be continued with nafcillin for injection, usp. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nafcillin for injection and other antibacterial drugs, nafcillin for injection should be used only to treat or prevent infections that are proven or strongly sus

United States - English - NLM (National Library of Medicine)

claris lifesciences, inc - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 32 mg in 50 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections; nitrogen; sodium hydroxide - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mesna, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; nitrogen; water for injections; disodium edetate - for the reduction and prevention of urinary tract toxicity (haemorrhagic cystitis) of oxazaphosphorines (see adverse effects sections of the cyclophosphamide and ifosfamide product information).